AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15083372 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity pedaling exercise
Number of subjects: 12
Study 15083372 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-intensity pedaling exercise
Number of subjects: 12
Study 15083372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pedaling exercise
Number of subjects: 12
Study 15083372 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 12
Study 15083372 — intervention group
Group type: EXPERIMENTAL
Intervention: No-go P300 amplitude
Number of subjects: 12
Study 11254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of malaria parasites in cord blood
Number of subjects: 658
Study 11254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal asthma
Number of subjects: 658
Study 11254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cord blood total IgE
Number of subjects: 658
Study 11254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical episodes of malaria during infancy
Number of subjects: 658
Study 11254820 — intervention group
Group type: EXPERIMENTAL
Intervention: Levels of indoor aeroallergens
Number of subjects: 658
Study 9813535 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand (Trachlight)
Number of subjects: 40
Study 9813535 — intervention group
Group type: COMPARATOR
Intervention: Direct-vision laryngoscopy (Macintosh laryngoscope)
Number of subjects: 40
Study 7719523 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 78
Study 7719523 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 78
Study 7719523 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 78
Study 2535870 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 2535870 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation (10 mg per day)
Number of subjects: 0
Study 2535870 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 0
Study 30941799 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-peer-reared (MPR)
Number of subjects: 97
Study 30941799 — intervention group
Group type: COMPARATOR
Intervention: Nursery-reared (NR)
Number of subjects: 97
Study 30941799 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 97
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pregnancy presence of similar symptoms
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent UTI
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: High hip circumference
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercising
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction of labor
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Forceps delivery
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: 3rd degree perineal tear
Number of subjects: 1482
Study 28525825 — intervention group
Group type: COMPARATOR
Intervention: Cesarean section
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosed depression (pre-pregnancy)
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI (pre-pregnancy)
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Strenuous exercising (pre-pregnancy)
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent UTI (pre-pregnancy)
Number of subjects: 1482
Study 28525825 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower educational achievement (pre-pregnancy)
Number of subjects: 1482
Study 26489389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (two 4 mg tablets taken orally at least 1 hour before radiation treatment and daily for 4 days after)
Number of subjects: 298
Study 26489389 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two placebo tablets taken orally at least 1 hour before radiation treatment and daily for 4 days after)
Number of subjects: 298
Study 26489389 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 298
Study 26489389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 23551928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual health intervention
Number of subjects: 70
Study 21555331 — intervention group
Group type: EXPERIMENTAL
Intervention: CRF(1) receptor antagonist R317573, 40 mg for 7 days
Number of subjects: 32
Study 21555331 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam (LZP), 2 mg as positive control on day 8
Number of subjects: 32
Study 21555331 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLAC)
Number of subjects: 32
Study 18423871 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treated (ET)
Number of subjects: 401
Study 18423871 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (CM)
Number of subjects: 401
Study 17061013 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted training program plus the TSF manual
Number of subjects: 25
Study 17061013 — intervention group
Group type: COMPARATOR
Intervention: Manual only
Number of subjects: 25
Study 14501734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin once daily
Number of subjects: 263
Study 14501734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg tamsulosin once daily
Number of subjects: 263
Study 14501734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 14501734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 or 0.8 mg once daily) long-term
Number of subjects: 263
Study 10936115 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhalers (MDIs) with Nebulizer Chronologs (NCs) monitoring
Number of subjects: 101
Study 10936115 — intervention group
Group type: COMPARATOR
Intervention: Participants with full foreknowledge of the MDI monitoring capability of the NC
Number of subjects: 101
Study 10936115 — intervention group
Group type: EXPERIMENTAL
Intervention: NC data for dumpers
Number of subjects: 101
Study 9062840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral lifestyle intervention (weight loss goals of 5 to 15 lb, 20 weekly group meetings)
Number of subjects: 535
Study 9062840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral lifestyle intervention
Number of subjects: 535
Study 9062840 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 535
Study 7995674 — intervention group
Group type: EXPERIMENTAL
Intervention: The Experimental Behavioral and Attitudinal Modification Project
Number of subjects: 0
Study 7995674 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3400411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg oral fast dissolving drug formulation (FDDF)
Number of subjects: 0
Study 3400411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31451520 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI) during surveillance
Number of subjects: 15
Study 31451520 — intervention group
Group type: COMPARATOR
Intervention: Clinical identification of high risk prior to endpoint in surveillance group
Number of subjects: 15
Study 31451520 — intervention group
Group type: EXPERIMENTAL
Intervention: Autofluorescence imaging (AFI) during surgery
Number of subjects: 15
Study 31451520 — intervention group
Group type: COMPARATOR
Intervention: Clinical identification of high risk prior to endpoint in surgery group
Number of subjects: 15
Study 29206996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil-based CRT with oxaliplatin
Number of subjects: 1179
Study 29206996 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-based CRT alone
Number of subjects: 1179
Study 29206996 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 0 + 1 (poor regression)
Number of subjects: 1179
Study 29206996 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 2 + 3 (intermediate regression)
Number of subjects: 1179
Study 29206996 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 4 (complete regression)
Number of subjects: 1179
Study 29206996 — intervention group
Group type: EXPERIMENTAL
Intervention: TRG 2 + 3 vs TRG 0 + 1
Number of subjects: 1179
Study 26425703 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab 6 mg/kg IV in 90 min (n = 46)
Number of subjects: 54
Study 26425703 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl, n = 8)
Number of subjects: 54
Study 23419655 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS)
Number of subjects: 74
Study 23419655 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer (XL)
Number of subjects: 74
Study 23419655 — intervention group
Group type: COMPARATOR
Intervention: No rate sensor (DDD)
Number of subjects: 74
Study 21144106 — intervention group
Group type: EXPERIMENTAL
Intervention: Konjac glucomannan (KGM) 4.5 g/d
Number of subjects: 0
Study 21144106 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maize starch)
Number of subjects: 0
Study 19239860 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Number of subjects: 0
Study 19239860 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 16939022 — intervention group
Group type: EXPERIMENTAL
Intervention: Crest SpinBrush Pro Clean (power toothbrush)
Number of subjects: 50
Study 16939022 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (ADA reference)
Number of subjects: 50
Study 14997962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 23
Study 14997962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 23
Study 14997962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 23
Study 14997962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10849526 — intervention group
Group type: EXPERIMENTAL
Intervention: IFO+GM‐CSF
Number of subjects: 56
Study 10849526 — intervention group
Group type: COMPARATOR
Intervention: CY+GM‐CSF
Number of subjects: 56
Study 9085304 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapanol (24-hourly)
Number of subjects: 24
Study 9085304 — intervention group
Group type: COMPARATOR
Intervention: MS Contin (12-hourly)
Number of subjects: 24
Study 9085304 — intervention group
Group type: EXPERIMENTAL
Intervention: Kapanol
Number of subjects: 24
Study 9085304 — intervention group
Group type: COMPARATOR
Intervention: MS Contin
Number of subjects: 24
Study 8210613 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (4 mg)
Number of subjects: 9
Study 8210613 — intervention group
Group type: COMPARATOR
Intervention: Carbon monoxide (320 p.p.m.)
Number of subjects: 9
Study 3327353 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acetylsalicylic acid (ASA)
Number of subjects: 82
Study 3327353 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine-heparin (DHEH)
Number of subjects: 82
Study 3327353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ASA and DHEH
Number of subjects: 82
Study 29739654 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic teaching
Number of subjects: 213
Study 29739654 — intervention group
Group type: COMPARATOR
Intervention: Video-based social learning
Number of subjects: 213
Study 27573564 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg bid)
Number of subjects: 108
Study 27573564 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin (SorCDDP: sorafenib 400 mg bid; cisplatin 65 mg/m2, day 1, every 4-6 weeks)
Number of subjects: 108
Study 26082887 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter volume reduction analysis using SPM8 plus DARTEL in CBS patients
Number of subjects: 83
Study 26082887 — intervention group
Group type: EXPERIMENTAL
Intervention: White matter volume reduction analysis using SPM8 plus DARTEL in RS patients
Number of subjects: 83
Study 26082887 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of CBS and RS VOIs
Number of subjects: 83
Study 26082887 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 83
Study 23043164 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogs with rHuPH20
Number of subjects: 14
Study 23043164 — intervention group
Group type: COMPARATOR
Intervention: Insulin analogs without rHuPH20
Number of subjects: 14
Study 20881606 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine-ER 5 mg/d
Number of subjects: 63
Study 20881606 — intervention group
Group type: EXPERIMENTAL
Intervention: amlodipine 5 mg/d
Number of subjects: 63
Study 20881606 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 17940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 5
Study 17940902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 15940143 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 230
Study 15940143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixture of 4 probiotic strains (MIX)
Number of subjects: 230
Study 15940143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 12828690 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpura-level treatment (0.5 J/cm2 greater than the purpura threshold)
Number of subjects: 11
Study 12828690 — intervention group
Group type: COMPARATOR
Intervention: Purpura-free treatment (1.0 J/cm2 less than the purpura threshold)
Number of subjects: 11
Study 12828690 — intervention group
Group type: EXPERIMENTAL
Intervention: Purpura-level treatment
Number of subjects: 11
Study 12828690 — intervention group
Group type: COMPARATOR
Intervention: Purpura-free treatment
Number of subjects: 11
Study 12828690 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (purpura and purpura-free)
Number of subjects: 11
Study 8692505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Number of subjects: 120
Study 8692505 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study 1804645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 1804645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 1804645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 0
Study 1804645 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 0
Study 1804645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6376016 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar mini‐tablets (5 g t.i.d.)
Number of subjects: 79
Study 29941062 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ACT
Number of subjects: 180
Study 29941062 — intervention group
Group type: COMPARATOR
Intervention: Brief ACT
Number of subjects: 180
Study 29941062 — intervention group
Group type: COMPARATOR
Intervention: EC
Number of subjects: 180
Study 27543734 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezable bottle
Number of subjects: 80
Study 27543734 — intervention group
Group type: COMPARATOR
Intervention: Syringe
Number of subjects: 80
Study 25759001 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased insurance payments (full insurance support for children under 5 years old)
Number of subjects: 30
Study 25759001 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonus payments to hospital staff
Number of subjects: 30
Study 25759001 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 25123988 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 2% solution applied after deodorant/antiperspirant to shaved axillae
Number of subjects: 30
Study 25123988 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 2% solution applied to unshaved axillae
Number of subjects: 30
Study 25123988 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including deodorant/antiperspirant and shaved/unshaved axillae)
Number of subjects: 30
Study 25123988 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 30
Study 22044402 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04457845 (single dose)
Number of subjects: 0
Study 22044402 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04457845 (multiple dose)
Number of subjects: 0
Study 22044402 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-04457845 (up to 40 mg single dose and 8 mg once daily for 14 days)
Number of subjects: 0
Study 22044402 — intervention group
Group type: COMPARATOR
Intervention: PF-04457845
Number of subjects: 0
Study 21039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl isothiocyanate (AITC)
Number of subjects: 85
Study 21039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylisothiocyanate (BITC)
Number of subjects: 85
Study 21039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylethylisothiocyanate (PEITC)
Number of subjects: 85
Study 21039313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulforaphane (SFN)
Number of subjects: 85
Study 17384828 — intervention group
Group type: COMPARATOR
Intervention: VVI pacing mode
Number of subjects: 27
Study 17384828 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing mode
Number of subjects: 27
Study 15867038 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line blood gas and chemistry monitor
Number of subjects: 93
Study 11952486 — intervention group
Group type: EXPERIMENTAL
Intervention: Fucidic acid (1.0%) eye drops applied twice per day
Number of subjects: 456
Study 11952486 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (0.5%) eye drops applied six times per day
Number of subjects: 456
Study 9708589 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information about complications from allogeneic blood transfusions
Number of subjects: 412
Study 9708589 — intervention group
Group type: COMPARATOR
Intervention: Prior knowledge (uninformed group)
Number of subjects: 412
Study 9708589 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information
Number of subjects: 412
Study 7624190 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded vision and visual imagery
Number of subjects: 80
Study 7624190 — intervention group
Group type: COMPARATOR
Intervention: Visual imagery
Number of subjects: 80
Study 7624190 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded vision subjects
Number of subjects: 80
Study 2374773 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (2,500 lux) for 2 hours daily
Number of subjects: 42
Study 2374773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dim light (50 lux) for 2 hours daily
Number of subjects: 42
Study 115046 — intervention group
Group type: EXPERIMENTAL
Intervention: Decanoate of flupenthixol
Number of subjects: 51
Study 115046 — intervention group
Group type: COMPARATOR
Intervention: Decanoate of fluphenazine
Number of subjects: 51
Study 115046 — intervention group
Group type: COMPARATOR
Intervention: Both drugs (flupenthixol and fluphenazine)
Number of subjects: 51
Study 31978436 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal iliac artery balloon occlusion
Number of subjects: 40
Study 31978436 — intervention group
Group type: COMPARATOR
Intervention: Standard management (Control)
Number of subjects: 40
Study 30950656 — intervention group
Group type: COMPARATOR
Intervention: Normal weight patients (BMI 18.5 kg/m2 ≤ BMI < 25 kg/m2)
Number of subjects: 2153
Study 30950656 — intervention group
Group type: COMPARATOR
Intervention: Overweight patients (BMI 25 kg/m2 ≤ BMI < 30 kg/m2)
Number of subjects: 2153
Study 30950656 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patients (BMI ≥30 kg/m2)
Number of subjects: 2153
Study 28122207 — intervention group
Group type: EXPERIMENTAL
Intervention: Advergame promoting energy-dense snacks
Number of subjects: 597
Study 28122207 — intervention group
Group type: COMPARATOR
Intervention: Advergame promoting nonfood products
Number of subjects: 597
Study 25982025 — intervention group
Group type: EXPERIMENTAL
Intervention: MenPF-1 vaccine (25 μg or 50 μg doses)
Number of subjects: 52
Study 23896353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cortisol (100mg)
Number of subjects: 10
Study 23896353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22024004 — intervention group
Group type: EXPERIMENTAL
Intervention: Strongest Families intervention (treatment)
Number of subjects: 243
Study 22024004 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 243
Study 19526040 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy with GTN (0.6 mg/h 24 h/day for 7 days)
Number of subjects: 28
Study 19526040 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 28
Study 16904524 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical intervention including an information session, the use of a pain diary, and the possibility to contact a physician to adjust the pain medication
Number of subjects: 64
Study 16904524 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment of pain by the staff radiation oncologist
Number of subjects: 64
Study 15265053 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (0.1, 0.25, 0.5, 1, 2.5, 5, and 10 mg)
Number of subjects: 55
Study 15265053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 15265053 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (10 mg)
Number of subjects: 55
Study 15265053 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS (5 and 10 mg)
Number of subjects: 55
Study 11590675 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 197
Study 11590675 — intervention group
Group type: COMPARATOR
Intervention: Secondary stenting
Number of subjects: 197